Carboplatin Enhances the Activity of Human Transient Receptor Potential Ankyrin 1 through the Cyclic AMP-Protein Kinase A-A-Kinase Anchoring Protein (AKAP) Pathways

Carboplatin, an anticancer drug, often causes chemotherapy-induced peripheral neuropathy (PN). Transient receptor potential ankyrin 1 (TRPA1), a non-selective cation channel, is a polymodal nociceptor expressed in sensory neurons. TRPA1 is not only involved in pain transmission, but also in allodynia or hyperalgesia development. However, the effects of TRPA1 on carboplatin-induced PN is unclear. We revealed that carboplatin induced mechanical allodynia and cold hyperalgesia, and the pains observed in carboplatin-induced PN models were significantly suppressed by the TRPA1 antagonist HC-030031 without a change in the level of TRPA1 protein. In cells expressing human TRPA, carboplatin had no effects on changes in intracellular Ca2+ concentration ([Ca2+]i); however, carboplatin pretreatment enhanced the increase in [Ca2+]i induced by the TRPA1 agonist, allyl isothiocyanate (AITC). These effects were suppressed by an inhibitor of protein kinase A (PKA). The PKA activator forskolin enhanced AITC-induced increase in [Ca2+]i and carboplatin itself increased intracellular cyclic adenosine monophosphate (cAMP) levels. Moreover, inhibition of A-kinase anchoring protein (AKAP) significantly decreased the carboplatin-induced enhancement of [Ca2+]i induced by AITC and improved carboplatin-induced mechanical allodynia and cold hyperalgesia. These results suggested that carboplatin induced mechanical allodynia and cold hyperalgesia by increasing sensitivity to TRPA1 via the cAMP-PKA-AKAP pathway.

[1]  Chilman Bae,et al.  Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain , 2019, Molecular pain.

[2]  Wuping Sun,et al.  Huachansu suppresses TRPV1 up-regulation and spinal astrocyte activation to prevent oxaliplatin-induced peripheral neuropathic pain in rats. , 2019, Gene.

[3]  N. Braidy,et al.  Thermo-Sensitive TRP Channels: Novel Targets for Treating Chemotherapy-Induced Peripheral Pain , 2017, Front. Physiol..

[4]  K. Taguchi,et al.  Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity , 2017, Neuropeptides.

[5]  Y. Mori,et al.  Distinct Mechanism of Cysteine Oxidation-Dependent Activation and Cold Sensitization of Human Transient Receptor Potential Ankyrin 1 Channel by High and Low Oxaliplatin , 2017, Front. Physiol..

[6]  T. Nakagawa,et al.  Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy. , 2017, Biological & pharmaceutical bulletin.

[7]  M. Glucksman,et al.  A-Kinase Anchoring Protein 79/150 Scaffolds Transient Receptor Potential A 1 Phosphorylation and Sensitization by Metabotropic Glutamate Receptor Activation , 2017, Scientific Reports.

[8]  Y. Uezono,et al.  Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats , 2015, Scientific Reports.

[9]  E. Kil,et al.  Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation , 2015, PloS one.

[10]  Takuhiro Yamaguchi,et al.  Tramadol and Its Metabolite M1 Selectively Suppress Transient Receptor Potential Ankyrin 1 Activity, but Not Transient Receptor Potential Vanilloid 1 Activity , 2015, Anesthesia and analgesia.

[11]  Weijie Zhang,et al.  Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1 , 2015, Translational neuroscience.

[12]  M. Kelley,et al.  Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, Oxaliplatin, or Carboplatin Induced Sensory Neuropathy , 2014, PloS one.

[13]  Y. Uezono,et al.  Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. , 2014, Journal of pharmacological sciences.

[14]  Y. Uezono,et al.  Palliation of Bone Cancer Pain by Antagonists of Platelet-Activating Factor Receptors , 2014, PloS one.

[15]  C. Ghelardini,et al.  A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain , 2013, Scientific Reports.

[16]  G. Aldini,et al.  Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. , 2013, Cancer research.

[17]  D. Simone,et al.  Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy , 2012, The Journal of Neuroscience.

[18]  N. Morioka,et al.  Activation of transient receptor potential ankyrin 1 evokes nociception through substance P release from primary sensory neurons , 2012, Journal of neurochemistry.

[19]  Shuji Kaneko,et al.  Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice , 2012, Molecular pain.

[20]  Z. J. Wang,et al.  Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain , 2011, Neuroscience.

[21]  B. Nilius,et al.  Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation , 2011, PAIN®.

[22]  N. Ozaki,et al.  Upregulations of P2X3 and ASIC3 involve in hyperalgesia induced by cisplatin administration in rats , 2010, PAIN®.

[23]  J. Calixto,et al.  The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation , 2010, PAIN®.

[24]  P. Anand,et al.  Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons , 2010, Molecular pain.

[25]  C. Loprinzi,et al.  Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice , 2010, Molecular pain.

[26]  A. Akopian,et al.  A-kinase anchoring protein mediates TRPV1 thermal hyperalgesia through PKA phosphorylation of TRPV1 , 2008, PAIN.

[27]  P. McNaughton,et al.  Proinflammatory Mediators Modulate the Heat-Activated Ion Channel TRPV1 via the Scaffolding Protein AKAP79/150 , 2008, Neuron.

[28]  S. Jordt,et al.  TRPA1 is a major oxidant sensor in murine airway sensory neurons. , 2008, The Journal of clinical investigation.

[29]  Yi Dai,et al.  Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. , 2008, Brain : a journal of neurology.

[30]  Wolfgang Grisold,et al.  Chemotherapy‐induced neuropathy , 2008, Journal of the peripheral nervous system : JPNS.

[31]  Shigeo Kobayashi,et al.  Activation of transient receptor potential ankyrin 1 by hydrogen peroxide , 2008, The European journal of neuroscience.

[32]  A. Patapoutian,et al.  A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition , 2007, Molecular pain.

[33]  L. Langeberg,et al.  Distinct enzyme combinations in AKAP signalling complexes permit functional diversity , 2005, Nature Cell Biology.

[34]  K. Bölcskei,et al.  Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice , 2005, Pain.

[35]  T. Hambley,et al.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs , 2000, British Journal of Cancer.

[36]  J. Lotz,et al.  Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[37]  G. Cavaletti,et al.  Carboplatin toxic effects on the peripheral nervous system of the rat. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  L. Langeberg,et al.  Coordination of Three Signaling Enzymes by AKAP79, a Mammalian Scaffold Protein , 1996, Science.

[39]  G. Bolis.  Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. , 1995, Seminars in oncology.

[40]  T. Shea,et al.  A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. , 1995, Seminars in oncology.

[41]  L. Langeberg,et al.  Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. , 1995, Science.

[42]  H. Homesley,et al.  Cancers of the uterine cervix and endometrium: major issues and future research directions. , 1994, Seminars in oncology.

[43]  I. Utsunomiya,et al.  Transient Receptor Potential Ankyrin 1 that is Induced in Dorsal Root Ganglion Neurons Contributes to Acute Cold Hypersensitivity after Oxaliplatin Administration. , 2015, Molecular pain.

[44]  A. Adjei,et al.  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Cornetta,et al.  Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. , 1995, Bone marrow transplantation.

[46]  J. Ruckdeschel.  The future role of carboplatin. , 1994, Seminars in oncology.